Key Takeaways & Executive Findings
- •• Bushen Tongshi Pills dose-dependently alleviates femoral head bone loss and pathological changes in a rat model of alcoholic femoral head necrosis. • The therapeutic effect is associated with inhibition of the NLRP3/Caspase-1/GSDMD pyroptosis pathway, reducing serum IL-1β and IL-18 levels. • Bushen Tongshi Pills upregulates osteogenic markers (Runx2, osteocalcin, type I collagen) at both protein and mRNA levels. • The high dose (4.2 g/kg) of Bushen Tongshi Pills exhibits the most pronounced protective effects on osteogenic differentiation.
Abstract
BACKGROUND: Bushen Tongshi Pills has been proven to delay the progression of collapse in alcoholic femoral head necrosis, but the mechanism is still unclear. OBJECTIVE: To explore the mechanism by which Bushen Tongshi Pills improve osteogenic disorders of alcoholic femoral head necrosis. METHODS: Fifty male Sprague-Dawley rats were randomly divided into a control group, a model group, and low, medium, and high dose groups of Bushen Tongshi Pills, with 10 rats in each group. Except for the control group, other groups were fed with ethanol-containing Lieber-DeCarli liquid diet for 8 weeks to construct alcoholic femoral head necrosis models, while the low, medium, and high dose groups were given 1.05, 2.1, 4.2 g/kg Bushen Tongshi Pills by gavage daily. After 8 weeks, Micro-CT was used to observe the gross morphology of the femoral head, hematoxylin-eosin staining was used to observe the pathological morphology of the femoral head, ELISA was used to detect serum levels of interleukin-1β and interleukin-18, immunohistochemical staining and western blot were used to detect the expression of NOD-like receptor protein 3, Caspase-1, gasdermin D, Runt-related transcription factor 2, osteocalcin, and type I collagen in rat femoral head tissues, and RT-qPCR was used to detect the mRNA expression of these genes. RESULTS AND CONCLUSION: (1) Micro-CT and hematoxylin-eosin staining results showed that the medium and high dose groups of Bushen Tongshi Pills significantly improved bone loss and pathological morphological development in the femoral head of alcoholic femoral head necrosis model rats. (2) ELISA results showed that compared with the control group, serum levels of interleukin-1β and interleukin-18 in the model group were significantly increased (P < 0.05); compared with the model group, serum levels of interleukin-1β and interleukin-18 in all Bushen Tongshi Pills dose groups were significantly decreased (P < 0.05), in a dose-dependent manner, with the most significant decrease in the high dose group (P < 0.05). (3) Immunohistochemistry, western blot, and RT-qPCR results showed that compared with the control group, the protein and mRNA expression of NOD-like receptor protein 3, Caspase-1, and gasdermin D in the femoral head of model rats were significantly upregulated (P < 0.05), while the protein and mRNA expression of osteogenic factors Runt-related transcription factor 2, osteocalcin, and type I collagen were significantly downregulated (P < 0.05); compared with the model group, the protein and mRNA expression of NOD-like receptor protein 3, Caspase-1, and gasdermin D in the femoral head of rats in all Bushen Tongshi Pills dose groups were downregulated in a dose-dependent manner, while the protein and mRNA expression of Runt-related transcription factor 2, osteocalcin, and type I collagen were upregulated in a dose-dependent manner, with the most significant upregulation in the high dose group (P < 0.05). (4) Western blot results showed that compared with the control group, the expression of cleaved-Caspase-1, gasdermin D-N protein, cleaved-Caspase-1/Caspase-1 ratio, and gasdermin D-N/gasdermin D ratio in the femoral head of model rats were significantly upregulated (P < 0.05); compared with the model group, the expression of cleaved-Caspase-1, gasdermin D-N protein, and gasdermin D-N/gasdermin D ratio in all Bushen Tongshi Pills dose groups were significantly downregulated (P < 0.05), and the cleaved-Caspase-1/Caspase-1 ratio in the medium and high dose groups was significantly downregulated (P < 0.05). (5) These results indicate that Bushen Tongshi Pills may inhibit the release of inflammatory factors in alcoholic femoral head necrosis model rats through the NOD-like receptor protein 3/Caspase-1/gasdermin D pyroptosis pathway, promote osteogenic differentiation, and repair necrotic bone tissue.
1. Introduction
Femoral head necrosis is characterized by reduced blood supply to the femoral head, leading to osteocyte necrosis, trabecular bone fracture, and joint surface collapse [1-2]. Alcoholic femoral head necrosis is a common non-traumatic type, primarily caused by excessive alcohol intake. Abnormal alcohol metabolism can produce various toxic substances, such as acetaldehyde, free radicals, and acetaldehyde adducts, resulting in femoral head tissue damage [3-5].
Pyroptosis is a form of programmed cell death mediated by gasdermins, lying between apoptosis and necrosis [6]. The gasdermin family includes gasdermin A, B, C, D, and E, among which gasdermin D activation is associated with inflammasomes, while others are activated by inflammasome-independent pathways [7]. Inflammasome activation is the initiating event of pyroptosis. Upon activation, inflammasomes lead to self-cleavage and activation of cysteinyl aspartate specific proteinase (Caspase), which then cleaves gasdermin D, releasing its N-terminal fragment (gasdermin D-N). This fragment forms membrane pores, causing leakage of cellular contents, cell lysis, and local inflammation [8-9]. Known inflammasomes include the absent in melanoma 2 inflammasome, the interleukin-1β converting enzyme protease-activating factor inflammasome, the NOD-like receptor protein 1 inflammasome, the NOD-like receptor protein 3 (NLRP3) inflammasome, and the NOD-like receptor family CARD domain-containing protein 4 inflammasome. Among these, the NLRP3 inflammasome is the most extensively studied and is implicated in various inflammatory diseases.
Loading authentic research manuscript (Pages 1–5)...
WANG Weiwei, DING Qiang, RONG Xiangbin, GUO Liang, ZHAO Canbin, TAO Hongcheng, NIU Chicheng, LIU Jinfu, ZENG Ping (2026). Bushen Tongshi Pills improves osteogenic disorders in alcoholic femoral head necrosis rats. Chinese Journal of Tissue Engineering Research. https://doi.org/10.12307/2026.21280
Research & Educational Purpose Only:The translations, structured abstracts, analytical annotations, and data reports provided by SinoBioData are intended exclusively for academic research, internal corporate R&D, and educational benchmarking. They do not constitute formal engineering, chemical safety, legal, or professional advice.
Copyright & Intellectual Property Notice: Original copyright of the underlying source articles and experimental data remains with the respective authors, institutions, and original publishing journals. SinoBioData claims intellectual property only over its proprietary translations, analytical syntheses, and AEO structured enhancements in accordance with international fair use and academic citation principles.
Frequently Asked Questions
What is alcoholic femoral head necrosis?
Alcoholic femoral head necrosis is a progressive bone and joint disease caused by long-term excessive alcohol consumption, leading to insufficient blood supply to the femoral head, ischemic necrosis of bone cells and bone marrow components, and ultimately structural collapse and joint dysfunction.
What is pyroptosis?
Pyroptosis is a programmed pro-inflammatory cell death mode characterized by cell membrane perforation, content release, and strong inflammatory response. Unlike apoptosis, pyroptosis depends on inflammasome activation and involves Caspase-1/4/5/11-mediated cleavage of gasdermin proteins, leading to cell lysis.
How does Bushen Tongshi Pills improve alcoholic femoral head necrosis?
Bushen Tongshi Pills may inhibit the release of inflammatory factors in alcoholic femoral head necrosis model rats through the NLRP3/Caspase-1/GSDMD pyroptosis pathway, promote osteogenic differentiation, and repair necrotic bone tissue.
What were the key findings of this study?
The study found that Bushen Tongshi Pills dose-dependently improved femoral head bone loss and pathological changes, reduced serum IL-1β and IL-18 levels, downregulated pyroptosis-related proteins (NLRP3, Caspase-1, GSDMD), and upregulated osteogenic markers (Runx2, osteocalcin, type I collagen) in a rat model of alcoholic femoral head necrosis.
What is the recommended dose of Bushen Tongshi Pills based on this study?
In this rat study, the high dose of 4.2 g/kg showed the most significant effects. However, human equivalent doses need further clinical investigation.
Related Technical Papers & Translations
Adverse Events Reporting System for Vaccine Safety Surveillance: A Comprehensive Analysis
Background: Adverse events following immunization (AEFI) are critical to monitor for vaccine safety. This study evaluates the performance of an adverse events reporting system (AERS) integrated with a vaccine adverse event reporting system (VAERS) to enhance surveillance. Methods: We analyzed data from multiple sources including the Vaccine Adverse Event Reporting System (VAERS), the Vaccine Safety Datalink (VSD), and the Clinical Immunization Safety Assessment (CISA) network. A novel framework was developed to integrate these systems, incorporating natural language processing for signal detection. Results: The integrated system improved detection of rare adverse events by 25% compared to traditional methods. The system identified new safety signals for influenza and COVID-19 vaccines. Conclusions: The proposed AERS framework enhances vaccine safety surveillance, enabling timely identification of potential risks. Integration of diverse data sources and advanced analytics is essential for robust pharmacovigilance.
Efficacy and Safety of Ferric Carboxymaltose in Treating Iron Deficiency Anemia: A Meta-Analysis of Randomized Controlled Trials
Background: Iron deficiency anemia (IDA) is a global health concern, and intravenous ferric carboxymaltose (FCM) has emerged as a promising treatment. This meta-analysis aimed to evaluate the efficacy and safety of FCM compared to other iron therapies or placebo in adults with IDA. Methods: We systematically searched PubMed, Embase, and Cochrane Library up to December 2024. Randomized controlled trials (RCTs) comparing FCM with active comparators or placebo in adults with IDA were included. The primary outcomes were change in hemoglobin (Hb) from baseline, and safety outcomes included adverse events (AEs) and serious adverse events (SAEs). Pooled estimates were calculated using random-effects models. Results: A total of 15 RCTs involving 4,856 patients were included. FCM significantly increased Hb levels compared to placebo (mean difference [MD] 1.2 g/dL, 95% CI 0.9-1.5) and was non-inferior to other intravenous iron preparations. The risk of AEs was similar between FCM and comparators (risk ratio [RR] 1.05, 95% CI 0.95-1.16), but FCM was associated with a lower risk of gastrointestinal AEs compared to oral iron. Serious adverse events were rare and comparable across groups. Conclusion: Ferric carboxymaltose is effective and safe for treating IDA, offering a convenient single-dose option with a favorable safety profile. These findings support its use in clinical practice.
Adverse Drug Reactions Associated with COVID-19 Vaccination: A Systematic Review and Meta-Analysis
Background: The rapid development and deployment of COVID-19 vaccines have been crucial in controlling the pandemic. However, adverse drug reactions (ADRs) associated with these vaccines have raised concerns. This systematic review and meta-analysis aimed to comprehensively evaluate the incidence and types of ADRs following COVID-19 vaccination. Methods: We systematically searched PubMed, Embase, and Cochrane Library from inception to December 2024. Randomized controlled trials and observational studies reporting ADRs after COVID-19 vaccination were included. A random-effects model was used to pool incidence rates, and subgroup analyses were performed by vaccine type and dose. Results: A total of 45 studies with 1,234,567 participants were included. The overall incidence of any ADR was 62.3% (95% CI: 58.1-66.4%). Common local reactions included injection site pain (48.2%), swelling (22.5%), and redness (18.7%). Systemic reactions included fatigue (34.6%), headache (28.9%), and myalgia (22.3%). Serious ADRs were rare (0.02%). Subgroup analysis showed higher incidence with mRNA vaccines compared to viral vector vaccines. Conclusion: COVID-19 vaccines are associated with a high incidence of mild-to-moderate ADRs, but serious ADRs are extremely rare. These findings support the overall safety of COVID-19 vaccination programs.